Azitra, Inc.AZTR

Azitra Inc. (CIK 1701478) is a clinical-stage biopharma company chasing a Fast Track FDA designation for EGFRi-associated rash, a skin condition tied to certain cancer therapies. The July 15 press release calls it 'a significant milestone,' but the numbers tell a quieter story: zero revenue in the company’s last audited 10-K for the year ended December 31, 2025. That’s not a rounding error; it’s the difference between the platform pitch and the balance sheet reality.

The company’s June 17 press release repeats the same FDA news, highlighting its 'engineered proteins and topical live biotherapeutics,' language designed to make the science sound imminent. Yet the latest 10-Q for the quarter ending March 31, 2026, shows $10.1 million in cash, $10.5 million in shareholders’ equity, and a net cash used in operations of $2.5 million. Translation: the company is spending faster than it’s earning, and the runway is shorter than the slide deck suggests.

The 10-Q also reports a net loss attributable to the parent of $3.9 million, operating loss of $3.9 million, and diluted EPS of negative $0.25 on 15.5 million diluted shares. Research and development expense clocked in at $1.6 million for the quarter, while capital expenditure was a mere $14,928-an oddly precise figure that underscores how early-stage the business remains. Liabilities stood at $1.6 million, leaving $10.5 million in shareholders’ equity, but the burn rate is the story.

Ownership filings add colour. A 13D filed June 24, 2026, shows an activist investor with a stake over 5%, while a 13G filed the next day labels another holder as passive at the same threshold. That’s not a trivial footnote; it’s a signal that views on the company’s prospects differ sharply. The filing index on SEC EDGAR lists these and more, but the pattern is clear: the company is still proving its technology while investors parse the tea leaves of governance.

For context, Azitra’s product pipeline hinges on FDA designations and clinical progress, neither of which is a guarantee of commercial success. The company’s own filings stress the preclinical to early-stage nature of its programmes, and the absence of revenue in its latest 10-K reinforces that point. The Fast Track designation is a procedural win, not a product launch.